Trial Profile
Prospective randomized study investigating safety and efficacy of Everolimus of preemptive prophylaxis of cytomegalovirus infection (CMV) in kidney transplant patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate mofetil
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 04 Nov 2015 New trial record
- 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation